Option chain shows key data for Achilles Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Achilles Therapeutics.

Achilles Therapeutics (NASDAQ:ACHL) Stock, Option Chain

Achilles Therapeutics

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Astra zenica

Equities

News

Markets

Movers

General

ACHL

Achilles Therapeutics announces a $12M deal with AstraZeneca for TRACERx data and plans job cuts following its strategic review.





Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts

Pharmaceuticals therapeutics

Shares of Achilles Therapeutics plc (NASDAQ: ACHL) are surging following a major strategic announcement from the company. The biotechnology firm revealed plans to discontinue its TIL-based cNeT program and close its ongoing Phase I/IIa clinical trials, CHIRON and THETIS.

Achilles Therapeutics Shares Are Trading Higher: What You Need To Know

Earnings

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Trading Ideas

ALUR

CADL

EFTR

TCBP

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday.

The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&amp;P 500 also fell, dropping, 0.28% to 5,197.03.

Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics PLC

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072845/Luckin-0227.png" alt="" class="wp-image-6724" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072845/Luckin-0227.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072845/Luckin-0227-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072845/Luckin-0227-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The company strengthened its position as China's leading coffee chain in last year's fourth quarter, as Starbucks looked for a new way forward in the ultra-competitive market

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Luckin reported strong triple-digit gains in its operating and net income in the fourth quarter, sparking an 8% rally in its shares</li>
<li>A weakened Starbucks is seeking a strategic partner for its $1 billion China business as consumers reject its pricey coffee in favor of cheap brews from its rivals</li>
</ul>
It was probably just a quirk of timing that&nbsp;Luckin Coffee Inc.&nbsp;(LKNCY.US) served up its&nbsp;<a href="https://www.globenewswire.com/news-release/2025/02/20/3029471/0/en/Luckin-Coffee-Announces-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results.html">latest quarterly results</a>&nbsp;on Feb. 20, a few weeks after local archrival&nbsp;Starbucks&nbsp;(SBUX.US) offered its own latest financial report card on Jan. 28. But the two reports were as different as black and white, as Luckin strengthened its position as leader of the overheated Chinese market while Starbucks remained in a state of disarray.
Luckin's fourth quarter earnings were nothing short of spectacular, following a rocky period for the company and its peers amid an ongoing price war. The company's revenue rose 36.1% year-over-year to 9.6 billion yuan ($1.3 billion) in last year's fourth quarter, while its operating income soared 368% to 995 million yuan, and net income rose 184% to 841 million yuan.
Its self-operated same-store sales continued to drop during the quarter, but the declines eased notably to down 3.4% from negative 13.1% in the previous quarter. CFO An Jing added to the positive news by saying the metric turned positive in December, ending three quarters of declines.
Investors applauded the report by bidding up Luckin shares by 8% the day of the announcement, though the stock gave back all those gains over the next four trading days.
Behind the numbers is a brutal competition for market share, as Luckin and chief low-cost rival&nbsp;Cotti Coffee&nbsp;have matched each other's aggressive price cuts over the past two years, both selling their premium brew for as little 9.9 yuan per cup. One of the biggest victims of those price wars has been Starbucks, which has largely stuck to its far higher premium prices.
Starbucks reported its revenue in China, its second-largest market after the U.S., rose by an anemic 1% to $743.6 million year-over-year in the final three months of last year. Its same-store China sales fell 6%, reversing a 10% increase a year earlier, while its average ticket fell by 4%, improving from a 9% decline a year earlier. Starbucks also said its transactions fell by 2% during the quarter, a sharp reversal from a 21% rise a year earlier, as China's increasingly cautious consumers opted for lower-cost options like Luckin and Cotti.
Starbucks hasn't exactly given up on China, despite the difficulties, and continues to open new stores. Its domestic store count of 7,685 at the end of last year was up by 10% from a year earlier, though that appears to be behind a previously announced goal of 9,000 stores by 2025. By comparison, Luckin had 22,340 stores as of the end of last year, up 37.5% year-on-year, which helps to explain its nearly identical revenue growth in the face of such fierce competition.
Starbucks isn't just sitting idly by as its China ship wobbles. Its longtime China chief left the company in January, and global CEO Brian Nicol confirmed he is looking for strategic partners to help turn the operation around. Companies mentioned as showing interest in the unit, which is valued at about $1 billion, include&nbsp;Meituan&nbsp;(3690.HK),&nbsp;China Resources&nbsp;and private equity firms&nbsp;PAG,&nbsp;KKR&nbsp;and&nbsp;FountainVest.
<h4 class="wp-block-heading">Coffee love affair</h4>
When Starbucks opened its first store in Beijing in 1999, it was the start of a love affair with barista-style coffee in a tea drinking nation. Fast forward to the end of 2024, when its China stores accounted for nearly a fifth of its global total, as Chinese millennials flocked to those stores as much for their upscale urban image as for its coffee.
But China's economic slowdown has changed all that, driving consumers to lower-cost options. Luckin and Cotti are catering to such coffee drinkers, with both recently indicating they have no plans to turn back the taps on the 9.9 yuan coffee wars.
Despite the intense competition, everyone is still eyeing a market with big growth potential. The market was worth an estimated $16 billion in 2025, only one-fifth the size of the U.S. at $90 billion, according to Statista, even though China's population is more than four times the U.S.
While Luckin is growing at lightning speed, Cotti, which was founded by Luckin's disgraced co-founders who left after a major accounting scandal, is growing even faster. Cotti has said it aims to have 50,000 stores by the end of 2025, partly by embedding its kiosks within other venues such as convenience stores and food and beverage outlets.
Cotti Chief Strategy Officer Li Yingbo said at a conference in November the company had lined up 50 retail partners for the initiative, including convenience store chain Meiyijia, fast-food operator Fujian Wallace Food Co. and budget hotel operator BTG Homeinns, with the potential to collectively add up to 100,000 new locations.
The company still has quite a bit of ground to cover to reach its 50,000-store goal. Last October it said it had 10,000 stores globally, 95% of those in China. But it reached that milestone just two years after opening its first store in Fuzhou, capital of Southern China's Fujian province.
Luckin's strategy includes investment in supply chain and production facilities to build up its operation, which is a combination of about two-thirds self-operated stores and one-third franchised. Last November, it signed a $1.38 billion agreement for the Brazilian Trade and Investment Promotion Agency to supply it with 240,000 metric tons of coffee over five years, an important hedge against rising coffee prices. Luckin also launched a new 570,000-square-foot roasting facility in the Eastern Chinese city of Suzhou last April and began construction of a new 3 billion yuan roastery and supply chain hub in Qingdao five months later.
Luckin has also announced international expansion plans, starting in Singapore, where it now has 51 stores. It had another two stores in Malaysia at the end of last year, and is reportedly eyeing the U.S. market, which would be a bold move into Starbucks' home turf.
Despite its consolidating position as China's coffee market leader, Luckin's valuation still looks lukewarm compared to Starbucks. It currently trades at a price-to-earnings (P/E) ratio of 24 and is valued at $8.4 billion, which are far cries from Starbucks' $130 billion market cap and P/E ratio of 37. Cotti is still a private company and is almost certainly still losing big money due to its aggressive tactics and early stage of development.
Dozens of analysts follow Starbucks, a proxy for the global consumer economy, while only four polled by Yahoo Finance follow Luckin, which withdrew its U.S. listing after the 2020 accounting scandal and now trades over-the-counter. But those analysts are betting heavily on the company. Of the three with ratings on Luckin, two give it a "buy" while the third gives it a "strong buy."

Asia

Restaurants

Exclusives

Starbucks' Struggle Vs. Luckin's Lead In China's Coffee Wars

Rosenblatt analyst Blair Abernethy maintains Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) with a Buy and maintains $62 price target.

Price Target

Analyst Ratings

Rosenblatt Maintains Buy on Bentley Systems, Maintains $62 Price Target

Baird analyst Mark Altschwager maintains TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) with a Outperform and raises the price target from $138 to $140.

Baird Maintains Outperform on TJX Companies, Raises Price Target to $140

Accelerating India's semiconductor transformation and solidifying its position in the industry's supply chain, VCI Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) ("VCI Global" or the "Company") is establishing India's first semiconductor wire manufacturing plant in partnership with Kinesis Manufacturing Solutions Sdn Bhd ("Kinesis"). This strategic initiative aligns with and supports the Indian government's effort to build a self-sustained semiconductor ecosystem.
The VCI Global-Kinesis plant will focus on producing semiconductor bonding wires, a crucial component in chip manufacturing. The 25,000-square-foot facility will be located in Chennai, with an initial investment of US$3.5 million. Operations are set to begin in the third quarter of 2025 with a single production line. By reaching mass production within the same quarter, the plant is projected to generate up to US$50 million, resulting in a return on investment (ROI) within 12 months. There are plans to expand to four production lines in the near future, aiming for an annual revenue of approximately US$200 million.

VCIG

VCI Global Invests $3.5M In India's Semiconductor Push, Partners With Kinesis To Launch India's First Semiconductor Wire Plant In Chennai, Targets $50M Revenue In First Year

Nautilus Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAUT#NASDAQ">NAUT</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is unchanged from the same period last year.

Earnings Beats

NAUT

Nautilus Biotechnology Q4 GAAP EPS $(0.14) Beats $(0.16) Estimate

Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $(0.12) by 258.33 percent. This is a 40.63 percent decrease over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $186.60 million which beat the analyst consensus estimate of $183.02 million by 1.95 percent. This is a 20.99 percent decrease over sales of $236.16 million the same period last year.

THRY

Thryv Holdings Q4 EPS $0.19 Beats $(0.12) Estimate, Sales $186.60M Beat $183.02M Estimate

Baird analyst Peter Benedict maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Outperform and raises the price target from $12 to $13.

ARHS

Baird Maintains Outperform on Arhaus, Raises Price Target to $13

Needham analyst Chris Pierce reiterates Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) with a Buy and maintains $10 price target.

Reiteration

JOBY

Needham Reiterates Buy on Joby Aviation, Maintains $10 Price Target

Biotech

QNRX

Quoin Pharmaceuticals Announces Whole Body' Data From Ongoing Pediatric Netherton Syndrome Study; Says Both Key Clinical Endpoints Demonstrated Significant Clinical Improvements From Baseline After Two Weeks Of Treatment With QRX003

Full-Year 2025 Outlook
<ul>
<li>Revenue range of $2.0 billion to $2.04 billion</li>
<li>Gross profit margin range of 51.5% to 53%</li>
<li>Adjusted EBITDA(2) range of $450 million to $475 million</li>
</ul>

Guidance

FTDR

Frontdoor 2025 Outlook: Expects Revenue Of $2B-$2.04B Vs. $1.943B Est.; Sees Adjusted EBITDA Between $450M-$475M And Gross Margin 51.5%-53%

Rosenblatt analyst Kevin Cassidy maintains Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and maintains $4 price target.

INVZ

Rosenblatt Maintains Buy on Innoviz Technologies, Maintains $4 Price Target

Needham analyst Mike Cikos reiterates Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Buy and maintains $75 price target.

PSTG

Needham Reiterates Buy on Pure Storage, Maintains $75 Price Target

Cars.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.14 by 250 percent. The company reported quarterly sales of $180.43 million which missed the analyst consensus estimate of $183.90 million by 1.88 percent. This is a 0.46 percent increase over sales of $179.61 million the same period last year.

Earnings Misses

CARS

Cars.com Q4 2024 Adj EPS $0.49 Beats $0.14 Estimate, Sales $180.43M Miss $183.90M Estimate

2025 guidance is as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$1,040 million - $1,050 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Transaction costs</td>
<td colspan="1" rowspan="1">~18.0% of revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)</td>
<td colspan="1" rowspan="1">$255 million to $265 million</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

PAYO

Payoneer Global Expects FY25 Revenue Of $1.04B-$1.05B Vs $1.035B Est

WIIM

ZVRA

Zevra Therapeutics shares are trading higher after the company announced it will sell its Pediatric Disease Priority Review Voucher for gross proceeds of $150 million.

Mizuho analyst Ben Chaiken maintains United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Underperform and raises the price target from $43 to $45.

PRKS

Mizuho Maintains Underperform on United Parks & Resorts, Raises Price Target to $45

Cronos Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) reported quarterly sales of $30.30 million which missed the analyst consensus estimate of $34.95 million by 13.29 percent. This is a 26.70 percent increase over sales of $23.91 million the same period last year.

CRON

Cronos Group Q4 Sales $30.30M Miss $34.95M Estimate

Full Year 2025 Outlook
<ul>
<li>The Company expects full-year 2025 Adjusted EBITDA attributable to stockholders excluding deferrals and recognitions to be in a range of $1.125 billion to $1.165 billion.
<ul>
<li>Guidance includes an estimated $25 million of incremental consumer financing interest expense attributable to a planned increase in non-recourse borrowing activity associated with the Company's Financing Business Optimization, as detailed below.</li>
<li>The Company intends to increase its average quarterly share repurchase goal to $150 million per quarter, from the current $100 million per quarter, to take advantage of the increased cash generated from its Financing Business Optimization program, and will continue to evaluate its share repurchase strategy with its Board of Directors on a routine basis.</li>
</ul>
</li>
</ul>

Hilton Grand Vacations FY25 Adjusted EBITDA Outlook $1.125B-$1.165B

Frontdoor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.11 by 145.45 percent. This is a 35 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $383.00 million which beat the analyst consensus estimate of $367.91 million by 4.10 percent. This is a 4.64 percent increase over sales of $366.00 million the same period last year.

Frontdoor Q4 2024 Adj EPS $0.27 Beats $0.11 Estimate, Sales $383.00M Beat $367.91M Estimate

Needham analyst David Saxon reiterates Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy and maintains $16 price target.

ATEC

Needham Reiterates Buy on Alphatec Holdings, Maintains $16 Price Target

Health Care

Press Releases

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Comments

Achilles Therapeutics

Achilles Therapeutics (ACHL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga